The introduction of nicotinamide as a nicotine substitute in e-cigarette and smokeless products and solutions represents an important regulatory obstacle for your FDA. Nicotinamide doesn't have nicotinic receptor agonist activity and is understood to work as a sedative at higher dosages6. The promises created by Nicotine River, ECBlend, as well as